Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Hideaki Yamakawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan; Department of Respiratory Medicine…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors (ICIs) are effective in advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50 %; however, responses remain heterogeneous. We investigated the predictive value of nutritional and inflammatory indices (Prognostic Nutritional Index [PNI], Geriatric Nutritional Risk Index [GNRI], and neutrophil-to-lymphocyte ratio [NLR]), for durable clinical benefit (DCB) and progression-free survival (PFS) in this population. METHODS: We retrospectively analyzed 125 patients (ECOG PS 0-2) with advanced NSCLC and PD-L1 ≥50 % treated with pembrolizumab. A composite score (0-3) was defined by PNI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan; Department of Respiratory Medicine, Tokyo Jikei University Hospital, 3-25-8 Nishi-shinbashi, Minato-ku,…
- Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan.
- Department of Respiratory Medicine, Tokyo Jikei University Hospital, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Zitieren
APA
Yamakawa, H., Kusano, K., Kawabe, R., Sato, S., Ohta, H., Nomaki, M., Oba, T., Uzuka, C., Akasaka, K., Amano, M., Matsushima, H., & Araya, J. (2026). Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101142
Vancouver
Yamakawa H, Kusano K, Kawabe R, Sato S, Ohta H, Nomaki M, et al. Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101142
BibTeX
@article{Yamakawa2026,
author = {Yamakawa, Hideaki and Kusano, Kenji and Kawabe, Rie and Sato, Shintaro and Ohta, Hiroki and Nomaki, Moe and Oba, Tomohiro and Uzuka, Chisa and Akasaka, Keiichi and Amano, Masako and Matsushima, Hidekazu and Araya, Jun},
title = {Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101142}
}
EUVIMED